CN110592056A - Phage lyase composite powder and preparation method and application thereof - Google Patents
Phage lyase composite powder and preparation method and application thereof Download PDFInfo
- Publication number
- CN110592056A CN110592056A CN201910884845.4A CN201910884845A CN110592056A CN 110592056 A CN110592056 A CN 110592056A CN 201910884845 A CN201910884845 A CN 201910884845A CN 110592056 A CN110592056 A CN 110592056A
- Authority
- CN
- China
- Prior art keywords
- lyase
- phage
- percent
- phage lyase
- composite powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000856 Lyases Proteins 0.000 title claims abstract description 110
- 102000004317 Lyases Human genes 0.000 title claims abstract description 109
- 239000000843 powder Substances 0.000 title claims abstract description 41
- 239000002131 composite material Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930195725 Mannitol Natural products 0.000 claims abstract description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 11
- 239000000594 mannitol Substances 0.000 claims abstract description 11
- 235000010355 mannitol Nutrition 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 5
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 27
- 230000006698 induction Effects 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 244000144972 livestock Species 0.000 claims description 10
- 244000144977 poultry Species 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000002028 Biomass Substances 0.000 claims description 6
- 239000003674 animal food additive Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 241001515965 unidentified phage Species 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims 3
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 239000003242 anti bacterial agent Substances 0.000 abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 229940088710 antibiotic agent Drugs 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 6
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 4
- 241000607142 Salmonella Species 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003746 feather Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 235000013594 poultry meat Nutrition 0.000 description 6
- 239000012137 tryptone Substances 0.000 description 6
- 235000021050 feed intake Nutrition 0.000 description 5
- 241000672609 Escherichia coli BL21 Species 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 3
- 229960004475 chlortetracycline Drugs 0.000 description 3
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 3
- 235000019365 chlortetracycline Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 101710097941 N-acetylmuramoyl-L-alanine amidase CwlA Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000520664 Spongia Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a phage lyase composite powder, which comprises 0.15-0.2% of phage lyase TSPpgh, 0.15-0.2% of phage lyase MMPpgh, 0.3-0.5% of trehalose, 0.1-0.2% of citric acid, 0.2-0.3% of mannitol, 0.2-0.3% of vitamin C and 98.3-98.9% of diatomite by mass percent; the phage lyase composite powder is used for in-vitro antibacterial activity detection by adopting a double-layer plate method, and is stored for 12 months at normal temperature, and the enzyme activity is kept above 95% (the enzyme activity loss is within 5%); the compound lyase preparation can be used for replacing antibiotics to inhibit proliferation of harmful pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus and the like in animal intestinal tracts and maintain intestinal tract microecological balance.
Description
Technical Field
The invention belongs to the technical field of enzyme preparations, and particularly relates to phage lyase composite powder as well as a preparation method and application thereof.
Background
The phage lyase is a cell wall hydrolase, can hydrolyze peptidoglycan, and after the phage infects a host, the double-stranded DNA phage destroys a bacterial cell wall structure through a cave protein-lyase cracking system, so that host bacteria are cracked. Lyases generally have two to three domains involved in catalysis and binding of substrates. As a novel bactericidal preparation, the high affinity of the lyase is related to the species-specific cell wall glycosyl, and the latter is an essential component for the survival of bacteria, so that the bacteria are difficult to generate resistance to the lyase, and in nature, almost all bacteria have corresponding phages, so that the development and research of the lyase have important value. The phage lyase lyses bacteria in two ways, namely "self-internal lysis" (lysine from internal) and "self-external lysis" (lysine from external), and when the purified phage lyase is cultured in combination with a host, the lyase degrades bacterial cell wall peptidoglycan, thereby killing the bacteria by lysis. The unique bacteriostatic mechanism of the phage lyase makes the phage lyase hopeful to replace antibiotics to treat bacterial infection, and can be used for clearing specific harmful flora in animal intestinal tracts and maintaining the health of the animal intestinal tracts.
Antibacterial drugs used as feed additives for a long time include sulfonamides, tetracyclines, penicillins, chloramphenicol, chlortetracycline, kanamycin, gentamicin and the like, and the harm is mainly expressed in that (1) bacteria generate drug resistance; (2) the immunity of the livestock and poultry body is reduced; (3) causing endogenous infection and secondary infection of livestock and poultry; (4) causing residues in the livestock and poultry products.
Food safety and health problems caused by the abuse of antibiotics are becoming more serious, the addition of antibiotics to the feed is prohibited in 2006 in the European Union, and the addition of antibiotics to the feed is also prohibited comprehensively in 2020 in China; the lyase is used as a novel bactericide and has 3 main characteristics; (1) specificity. The lyase only cleaves host bacteria and has no killing effect on other strains, and the specificity of the lyase can effectively avoid flora imbalance as an antibacterial drug. (2) High efficiency. Compared with antibiotics, lyase has stronger bactericidal activity. The same amount of strain is cracked, the sterilizing efficiency of the lyase is 12-24 times that of the antibiotic, and the biofilm can be eliminated. (3) And (4) safety. In a single-dose toxicity experiment, the experimental animals have no adverse reaction, important organs and tissues have no serious inflammatory reaction and other pathological changes, and the lyase is not easy to generate drug resistance. Is expected to replace antibiotics to become another way for inhibiting bacteria of animal intestinal tracts.
The phage lyase belongs to proteases and is easily interfered by gastric acid and bile salt in the direct feeding process; in addition, the large amount of pepsin and trypsin in animal gastrointestinal tract can decompose bacteriophage lyase, resulting in loss of its activity; and residues on the amino acids of the phage lyase are easily oxidized, resulting in reduced activity.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides phage lyase composite powder, which comprises 0.15-0.2% of phage lyase TSPpgh, 0.15-0.2% of phage lyase MMPpgh, 0.3-0.5% of trehalose, 0.1-0.2% of citric acid, 0.2-0.3% of mannitol, 0.2-0.3% of vitamin C and 98.3-98.9% of diatomite by mass percent.
The preparation method of the phage lyase composite powder comprises the following steps: respectively constructing a genetically engineered bacterium containing a phage lyase TSPpgh gene and a genetically engineered bacterium containing a phage lyase MMPpgh gene according to a conventional method, and culturing the successfully constructed genetically engineered bacterium at 35-38 ℃ and 100-300rmp/min for 10-12h until the biomass OD (OD) of the genetically engineered bacterium600=30-35, then induction with lactose, after an induction time of 5-6h, removal of the medium, resuspension with phosphate buffered saline, high-pressure homogenization disruption at a pressure of 1000-1100 bar, centrifugation to collect the supernatant and filtration with a filter having a pore size of 0.22 μm, sterile filtration of the supernatant containing the lyase TSPpgh, of the supernatant containing the lyase TSPpghMixing the supernatant of lyase MMPpgh with trehalose, citric acid, mannitol, vitamin C and diatomite, and drying to water content of 8-10% to obtain phage lyase composite powder.
The phage lyase TSPpgh and the phage lyase MMPpgh are disclosed in published patent application documents, the construction method of the recombinant expression vector is a conventional method, the genetic engineering strain for expressing the phage lyase TSPpgh and the phage lyase MMPpgh is Escherichia coli BL21, and the transformation method is also a conventional method.
The two phage lyase genes are respectively cloned on pET-28a (+) plasmids, and are transformed into escherichia coli BL21 after successful verification, so that the genetic engineering expression of phage lyase TSPpgh and phage lyase MMPpgh is realized.
The two phage lyases are prepared by fermentation, an LB culture medium is adopted as a seed culture medium and comprises the components of 10.0g/L of NaCl, 10.0g/L of tryptone and 5.0g/L, pH =7.0-7.2 of yeast powder, and the phage lyases are sterilized at 121 ℃ for 20 min; the components of the fermentation medium comprise NaCl 10.0g/L, tryptone 10.0g/L, yeast powder 5.0g/L, glucose 10 g/L, pH =7.0-7.5, sterilization is carried out at 115 ℃ for 20min, and the pH =7.0 is adjusted by 2mol/L NaOH in the fermentation process.
The induced lactose concentration is 20g/L, 50mL of lactose solution with the concentration is added into each liter of bacterial liquid, the induction temperature is 35-38 ℃, and the rotating speed is 120-150 rmp/min.
The carrier for adsorbing the phage lyase TSPpgh and MMPpgh is food-grade diatomite (Henan Jiekang environmental protection science and technology Limited), is white fine powder in character, is a biogenic siliceous sedimentary rock, mainly comprises ancient diatoms and siliceous parts of other tiny organisms such as actinomycetes, spongia spicata and the like, and the content of the diatoms reaches 90 percent; the diatomite is used as an adsorbent of the phage lyase, the loading capacity of the phage lyase can be effectively increased, the diatomite and the phage lyase can play a synergistic effect, and the diatomite can be uniformly dispersed when being added into feed and is bonded and mixed with feed particles, so that the diatomite is not easy to separate out; after eating, the livestock and poultry can promote digestion, adsorb bacteria in gastrointestinal tracts of the livestock and poultry and then discharge the bacteria out of bodies, enhance the physique of the animals and play a role in strengthening the muscles and the stomach.
Trehalose, mannitol and vitamin C are used as substances for improving the immunity of the organism and resisting aging, the trehalose, the mannitol and the vitamin C are used as enzyme protective agents, the antioxidant capacity and the heat stability of protease can be improved, the storage life of an enzyme preparation product can be prolonged, and citric acid can effectively enhance the bacteriostatic activity of lyase.
The invention also aims to apply the phage lyase composite powder to being used as a feed additive for livestock and poultry.
The phage lyase composite powder provided by the invention can effectively inhibit the proliferation of escherichia coli, salmonella and staphylococcus aureus, can replace an antibiotic additive in feed, and is used for removing harmful bacteria in intestinal tracts of livestock and poultry; can specifically kill bacteria in the lysis spectrum without interfering other flora in the intestinal tract, maintain the micro-ecological balance of the animal intestinal tract and enhance the capability of the animal to resist the infection of external pathogenic bacteria.
The two phage lyase are obtained from phages of Thermus TC16 and Thermus subsp TG17 separated from Tengchong hot sea, wherein the phage lyase TSPpgh has bacteriostatic activity within the range of 37-65 ℃, and the phage lyase MMPpgh has bacteriostatic activity within the range of 37-50 ℃.
The phage lyase composite powder can be stored for a long time at normal temperature, and experiments prove that the activity of the used phage lyase composite powder is still kept above 95 percent (the loss of the activity of the enzyme is within 5 percent) after 12 months of storage at normal temperature.
The phage lyase composite powder can effectively reduce the feed-weight ratio of white feather broilers, promote the daily weight gain of the white feather broilers while removing the blindgut pathogenic microorganisms of the white feather broilers, mainly comprising escherichia coli and salmonella, and effectively improve the bursa of Fabricius index, the cecal index and the like of the white feather broilers.
The use of antibiotics in large quantities has caused the emergence of drug-resistant bacteria and seriously threatened the health of human beings; the phage lyase is a special bacterial cell wall hydrolase, can specifically kill bacteria, cannot damage other beneficial flora, can effectively control the infection and proliferation of pathogenic bacteria, and is not easy to generate drug resistance; the phage lyase preparation is expected to replace antibiotics and become a new product for resisting bacterial diseases.
Detailed Description
The present invention is further illustrated by the following examples, without limiting the scope of the invention thereto; in the following examples, LB medium was used as the seed medium, and the components were NaCl 10.0g/L, tryptone 10.0g/L, yeast powder 5.0g/L, pH =7.0-7.2, sterilized at 121 ℃ for 20 min; the components of the fermentation medium comprise NaCl 10.0g/L, tryptone 10.0g/L, yeast powder 5.0g/L, glucose 10 g/L, pH =7.0-7.5, sterilization is carried out at 115 ℃ for 20min, and the pH =7.0 is adjusted by 2mol/L NaOH in the fermentation process.
Phosphate Buffered Saline (PBS): k2PHO4 0.27g、NaHPO41.42g, NaCl 8g and KCl 0.2g, adding deionized water, stirring for dissolving, adjusting pH to 7.4, diluting to 1L, and sterilizing at 121 deg.C for 20 min.
Example 1: the composition and the mass percentage of the phage lyase composite powder are 0.15 percent of phage lyase TSPpgh, 0.2 percent of phage lyase MMPpgh, 0.5 percent of trehalose, 0.1 percent of citric acid, 0.2 percent of mannitol, 0.2 percent of vitamin C and 98.65 percent of diatomite.
The preparation method of the phage lyase composite powder comprises the following steps: cloning phage lyase TSPpgh gene and phage lyase MMPpgh gene on pET-28a (+) plasmid respectively, transforming into Escherichia coli BL21 after successful verification to obtain genetically engineered bacterium containing phage lyase TSPpgh gene and genetically engineered bacterium containing phage lyase MMPpgh gene, inoculating 2 strains into 300mL seed culture medium, culturing at 37 deg.C to OD600=2.0, inoculated at 2% inoculum size into fermentation medium (20L automatic fermenter (Shanghai Bailun Biotech Co., Ltd.)), and cultured at 37 ℃ and 200rmp/min for 10h to OD of biomass of genetically engineered bacteria600=35；
Then, lactose is used for induction, the concentration of the induced lactose is 20g/L, and bacterial liquid is added in each liter50mL of lactose solution, wherein the host induction temperature for expressing the phage lyase TSPpgh is 37 ℃, the rotating speed is 150rmp/min, and the induction time is 5 h; the host induction temperature for expressing the phage lyase MMPpgh is 37 ℃, the rotating speed is 120rmp/min, and the induction time is 5 h; centrifuging to remove the medium, resuspending with phosphate buffered saline, and using the OD as the biomass for high pressure homogenate disruption600And =15, homogenizing and crushing under high pressure at 1000 bar, centrifuging at 13000r/min, collecting supernatant, filtering with a filter membrane with the aperture of 0.22 mu m, mixing the supernatant containing the lyase TSPpgh and the supernatant containing the lyase MMPpgh with trehalose, citric acid, mannitol, vitamin C and diatomite uniformly under an aseptic condition, drying by adopting a boiling method, wherein the air inlet temperature is 37 ℃, the air outlet temperature is 30 ℃, and drying until the water content is 8% to obtain the phage lyase composite powder.
Example 2: the components and the mass percentage of the phage lyase composite powder are 0.2 percent of phage lyase TSPpgh, 0.15 percent of phage lyase MMPpgh, 0.3 percent of trehalose, 0.2 percent of citric acid, 0.3 percent of mannitol, 0.3 percent of vitamin C and 98.55 percent of diatomite.
The preparation method of the phage lyase composite powder comprises the following steps: cloning phage lyase TSPpgh gene and phage lyase MMPpgh gene on pET-28a (+) plasmid respectively, transforming into Escherichia coli BL21 after successful verification to obtain genetically engineered bacterium containing phage lyase TSPpgh gene and genetically engineered bacterium containing phage lyase MMPpgh gene, inoculating 2 strains into 300mL seed culture medium, culturing at 37 deg.C to OD600=1.5, then inoculating to fermentation medium (20L automatic fermentation tank (Shanghai Bailun Biotech Co., Ltd)) with 1.5% inoculum size, culturing at 37 deg.C and 150rmp/min for 12h to obtain genetically engineered bacteria biomass OD600=30；
Then, lactose is used for induction, the concentration of the induced lactose is 20g/L, 50mL of lactose solution is added into each liter of bacterial liquid, the host induction temperature for expressing the phage lyase TSPpgh is 37 ℃, the rotating speed is 120rmp/min, and the induction time is 6 h; the host induction temperature for expressing the phage lyase MMPpgh is 37 ℃, the rotating speed is 150rmp/min, and the induction is carried outThe time is 6 h; centrifuging to remove the medium, resuspending with phosphate buffered saline, and using the OD as the biomass for high pressure homogenate disruption600And =20, carrying out high-pressure homogenate crushing under the pressure of 1100 bar, centrifuging at 13000r/min, collecting supernatant, filtering by using a filter membrane with the aperture of 0.22 mu m, mixing the supernatant containing the lyase TSPpgh and the supernatant containing the lyase MMPpgh with trehalose, citric acid, mannitol, vitamin C and diatomite uniformly under an aseptic condition, drying by adopting a boiling type, wherein the air inlet temperature is 37 ℃, the air outlet temperature is 30 ℃, and drying until the water content is 9% to obtain the phage lyase composite powder.
Example 3: in-vitro antibacterial activity detection of phage lyase composite powder
1. 1g of the phage lyase composite powder prepared in the above example is taken to be placed in a 4 mL EP tube, and 1g of sterilized diatomite is taken to be placed in the 4 mL EP tube as a control;
2. 3 mL of PBS is added into the experimental group and the control group respectively;
3. diluting to 10% in the experimental group and the control group respectively-5200 mu L of to-be-detected bacterial liquid;
4. after sufficient shaking, incubating in 37 ℃ water bath for 30min, shaking once every 5 min;
5. after incubation, taking 300 mu L of the culture medium to detect, and carrying out inverted culture at 37 ℃ for 12h to count colonies;
the lower layer solid culture medium comprises the following components: 10.0g/L NaCl, 10.0g/L tryptone, 5.0g/L yeast powder and 15.0 g/L agar powder;
the upper semi-solid medium comprises the following components: NaCl 10.0g/L, tryptone 10.0g/L, yeast powder: 5.0g/L, agar powder: 5.6 g/L;
escherichia coli for detection, strain number: CMC (B) 44102; salmonella paratyphi, strain number: CMCC (B) 50094; staphylococcus aureus, strain number: ATCC6538, provided by the university of kunming science and technology college; OD in use600=1.2-1.5。
The formula for calculating the bacteriostasis rate is as follows:
bacteriostasis rate (K)1) Number of colonies in control group-experimentGroup colony number/control group colony number × 100%;
the experimental result shows that the bacteriostatic rate of the phage lyase composite powder to host Escherichia coli (CMC (B) 44102) is 66.23%, the bacteriostatic rate to salmonella paratyphi (CMCC (B) 50094) is 78.3% and the bacteriostatic rate to staphylococcus aureus (ATCC 6538) is 85.2%.
Example 4: experiments as feed additives
Selecting 315 white feather broilers of 0 day old, randomly dividing the white feather broilers into 3 groups, namely a blank control group, a positive control group and a phage lyase experimental group, wherein each group is provided with 3 repeats; feeding a blank control group to a basic ration, adding aureomycin into the basic ration by a positive control group according to 50ppm/kg, and adding the phage lyase composite powder described in the embodiment 1 into a phage lyase experimental group according to 50 ppm/kg; the experimental period is 28 days, the feed intake and the body weight are recorded every day in the experimental process, weighing is carried out before early feeding on the 28 th day, 3 animals are randomly selected from each group for dissection, and immune organs are weighed; finally, the Average Daily Feed Intake (ADFI), the Average Daily Gain (ADG), the material-weight ratio (F/G) and the immune organ index (mg/G) are calculated, and the calculation formula is as follows:
average Daily Feed Intake (ADFI) = feed intake/number of experimental days
Average Daily Gain (ADG) = (end weight-initial weight)/number of days tested
Material-to-weight ratio (F/G) = average daily feed intake/average daily gain
Immune organ index (mg/g) = immune organ weight/body weight
The experimental results are shown below:
| average Daily Food Intake (ADFI) | Average Daily Gain (ADG) | Material to weight ratio (F/G) | Bursa index (mg/g) | Spleen index (mg/g) | |
| Blank control group | 25.404 | 10.344 | 0.347 | 1.169 | 1.164 |
| Positive control group | 28.826 | 16.131 | 0.256 | 1.272 | 1.852 |
| Phage lyase experimental group | 28.331 | 14.656 | 0.280 | 1.091 | 0.894 |
The experimental result shows that the material weight ratio (F/G): the blank control group is larger than the phage lyase test group and is larger than the positive control group, and the difference of the material weight ratio (F/G) of the positive control group and the phage lyase test group is not large, which shows that the phage lyase composite powder can be used as a feed additive to effectively reduce the broiler feed weight ratio (F/G) and is close to the action effect of aureomycin.
Immune organ index: the positive control group > the blank control group > the phage lyase experimental group, and the difference of immune organ indexes of the phage lyase experimental group and the blank control group is not large, which indicates that the phage lyase composite powder of the invention does not influence the immunity level of the broiler chicken.
Example 5: phage lyase composite powder storage activity tracking experiment
The activity of the phage lyase composite powder just prepared is defined as 100%, samples are respectively taken for antibacterial activity detection in 7 days, 15 days, 30 days, 90 days, 180 days and 360 days of storage, the detection method refers to example 3, and the activity rate of the phage lyase composite powder is calculated by the following formula.
Bacteriostatic rate (Kn) = number of control colony-experimental colony/number of control colony x 100%, wherein n is 0d, 7d, 15d, 30d, 90d, 180d, 360 d;
enzyme activity = bacteriostatic rate (Kn)/bacteriostatic rate (K)0d）×100%；
The results are shown in the following table:
| time of day | 0d | 7d | 15d | 30d | 90d | 180d | 360d |
| Rate of enzyme activity | 100% | 98% | 98% | 97.5% | 97% | 96% | 95.5% |
The tracking detection result of the enzyme activity shows that the loss of the enzyme activity is within 5 percent after the enzyme activity is stored for 360 days at normal temperature, and the characteristics of the finished product are not influenced.
Claims (3)
1. A phage lyase composite powder is characterized in that: the composition and the mass percentage are 0.15 to 0.2 percent of bacteriophage lytic enzyme TSPpgh, 0.15 to 0.2 percent of bacteriophage lytic enzyme MMPpgh, 0.3 to 0.5 percent of trehalose, 0.1 to 0.2 percent of citric acid, 0.2 to 0.3 percent of mannitol, 0.2 to 0.3 percent of vitamin C and 98.3 to 98.9 percent of diatomite.
2. The method for preparing a phage lytic enzyme complex powder of claim 1, comprising: respectively constructing a genetically engineered bacterium containing a phage lyase TSPpgh gene and a genetically engineered bacterium containing a phage lyase MMPpgh gene, and fermenting and culturing the successfully constructed genetically engineered bacterium at 35-38 ℃ and 300rmp/min for 10-12h until the biomass OD of the genetically engineered bacterium is reached600And =30-35, then using lactose for induction, removing the culture medium after the induction time is 5-6h, resuspending the culture medium by phosphate buffer solution, carrying out high-pressure homogenization and crushing under the pressure of 1000-1100 bar, centrifugally collecting the supernatant, filtering the supernatant by using a filter membrane with the pore diameter of 0.22 mu m, mixing the supernatant containing the lyase TSPpgh and the supernatant containing the lyase MMPpgh with trehalose, citric acid, mannitol, vitamin C and diatomite uniformly under the aseptic condition, and drying the mixture until the water content is 8-10% to obtain the phage lyase composite powder.
3. The use of the phage lyase complex powder of claim 1 as a feed additive for livestock and poultry, characterized in that: the feed additive can improve the immunity of livestock and poultry and increase the capability of the livestock and poultry for resisting the infection of exogenous pathogenic bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910884845.4A CN110592056A (en) | 2019-09-19 | 2019-09-19 | Phage lyase composite powder and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910884845.4A CN110592056A (en) | 2019-09-19 | 2019-09-19 | Phage lyase composite powder and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110592056A true CN110592056A (en) | 2019-12-20 |
Family
ID=68861206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910884845.4A Pending CN110592056A (en) | 2019-09-19 | 2019-09-19 | Phage lyase composite powder and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110592056A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110592057A (en) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | Chimeric lyase ILTphg and polynucleotides encoding same |
| CN111304181A (en) * | 2020-02-17 | 2020-06-19 | 华东理工大学 | Genetically engineered vibrio parahemolyticus phage lyase and preparation method and application thereof |
| CN111876400A (en) * | 2020-08-06 | 2020-11-03 | 昆明理工大学 | Normal temperature lyase Sly and polynucleotide for coding same |
| CN112143747A (en) * | 2020-09-09 | 2020-12-29 | 昆明理工大学 | Phage lyase, gene thereof, gene recombination expression vector and application |
| CN115428862A (en) * | 2021-06-02 | 2022-12-06 | 菲吉乐科(南京)生物科技有限公司 | Antibacterial product produced by bacteriophage and lyase and preparation method thereof |
| CN116036101A (en) * | 2023-01-29 | 2023-05-02 | 广东省农业科学院动物科学研究所 | Application of trehalose in medicines for improving drug-resistant bacteria sensitivity and assisting chicken disease-resistant breeding |
Citations (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1731134A1 (en) * | 2004-03-17 | 2006-12-13 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Functional powders |
| CN101690546A (en) * | 2009-09-29 | 2010-04-07 | 浙江师范大学 | Layer chicken feed additive and using method |
| CN102885206A (en) * | 2012-10-29 | 2013-01-23 | 曾伟 | Natural animal feed additive |
| CN103242996A (en) * | 2013-04-25 | 2013-08-14 | 湖南鸿鹰生物科技有限公司 | Compound enzyme for bear |
| CN103436514A (en) * | 2013-08-20 | 2013-12-11 | 昆明理工大学 | Heat-resistant lyase TSPpgh and polynucleotide coding same |
| CN103974715A (en) * | 2011-06-17 | 2014-08-06 | 哈洛齐梅公司 | Stable formulations of a hyaluronan-degrading enzyme |
| CN105102615A (en) * | 2013-03-14 | 2015-11-25 | 巴斯夫酶有限责任公司 | Phytase formulation |
| CN105263965A (en) * | 2013-03-15 | 2016-01-20 | 斯波根生物技术公司 | Fusion proteins and methods for stimulating plant growth, protecting plants, and immobilizing bacillus spores on plants |
| CN105309782A (en) * | 2015-10-21 | 2016-02-10 | 滁州红琊山养殖有限公司 | Orange-flavor pig feed flavoring agent |
| CN105558378A (en) * | 2015-12-30 | 2016-05-11 | 双胞胎（集团）股份有限公司 | Feed additive with effects in enhancing pig immunity and protecting nutrient components in feed |
| CN105961904A (en) * | 2016-06-22 | 2016-09-28 | 桂轩 | Feed formula of meat ducks |
| CN106071297A (en) * | 2016-06-08 | 2016-11-09 | 黄名珠 | A kind of duck feed that can improve egg production |
| US20160376263A1 (en) * | 2016-07-26 | 2016-12-29 | Senomyx, Inc. | Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof |
| US20170087199A1 (en) * | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
| CN106854247A (en) * | 2016-12-12 | 2017-06-16 | 华南农业大学 | A kind of preparation method of the bacterial virus catenase that can crack Escherichia coli and salmonella |
| CN106928908A (en) * | 2017-02-19 | 2017-07-07 | 广州市芯检康生物科技有限公司 | A kind of new aeroge multifunctional material and preparation method thereof |
| US9732071B2 (en) * | 2015-10-01 | 2017-08-15 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
| CN107156538A (en) * | 2017-06-03 | 2017-09-15 | 合肥雪立歆农业科技有限公司 | A kind of aquatic feeds of starch-containing adhesive and preparation method thereof |
| CN107468528A (en) * | 2016-06-07 | 2017-12-15 | 董玲 | A kind of lyophilized formulations and preparation method thereof |
| CN107771083A (en) * | 2015-04-23 | 2018-03-06 | 卡莱多生物科技有限公司 | Glycan therapeutic agent and treatment method |
| CN107828769A (en) * | 2017-09-28 | 2018-03-23 | 昆明理工大学 | A kind of heat-resisting lyases MMPpgh and the polynucleotides for encoding this enzyme |
| CN108056325A (en) * | 2018-01-08 | 2018-05-22 | 浙江大学舟山海洋研究中心 | A kind of seawater black porgy fish meal with immunological enhancement |
| CN108333263A (en) * | 2017-01-20 | 2018-07-27 | 北京蛋白质组研究中心 | A kind of detection method of Urine proteins preparation method and urine protein group |
| CN108342375A (en) * | 2018-03-22 | 2018-07-31 | 昆明三正生物科技（集团）有限公司 | A kind of Pintsch process enzymatic compositions |
| CN108392473A (en) * | 2017-02-07 | 2018-08-14 | 常州柚盾实业投资有限公司 | A kind of formula and preparation method thereof of the stable freeze-dried preparation containing active oil |
| CN108926493A (en) * | 2018-08-24 | 2018-12-04 | 广东丸美生物技术股份有限公司 | A kind of skin care mantle compound powder and the preparation method and application thereof |
| CN109106736A (en) * | 2017-06-25 | 2019-01-01 | 常州伟博海泰生物科技有限公司 | A kind of lyophilized excipient containing plant tissue |
| CN111032642A (en) * | 2017-06-29 | 2020-04-17 | 里格尔药品股份有限公司 | Kinase inhibitors and methods of making and using |
| CN112063538A (en) * | 2020-09-25 | 2020-12-11 | 中国农业科学院特产研究所 | Trichoderma hamatum, microbial agent containing trichoderma hamatum and application of trichoderma hamatum |
-
2019
- 2019-09-19 CN CN201910884845.4A patent/CN110592056A/en active Pending
Patent Citations (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1731134A1 (en) * | 2004-03-17 | 2006-12-13 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Functional powders |
| CN101690546A (en) * | 2009-09-29 | 2010-04-07 | 浙江师范大学 | Layer chicken feed additive and using method |
| CN103974715A (en) * | 2011-06-17 | 2014-08-06 | 哈洛齐梅公司 | Stable formulations of a hyaluronan-degrading enzyme |
| CN102885206A (en) * | 2012-10-29 | 2013-01-23 | 曾伟 | Natural animal feed additive |
| CN105102615A (en) * | 2013-03-14 | 2015-11-25 | 巴斯夫酶有限责任公司 | Phytase formulation |
| CN105263965A (en) * | 2013-03-15 | 2016-01-20 | 斯波根生物技术公司 | Fusion proteins and methods for stimulating plant growth, protecting plants, and immobilizing bacillus spores on plants |
| CN103242996A (en) * | 2013-04-25 | 2013-08-14 | 湖南鸿鹰生物科技有限公司 | Compound enzyme for bear |
| CN103436514A (en) * | 2013-08-20 | 2013-12-11 | 昆明理工大学 | Heat-resistant lyase TSPpgh and polynucleotide coding same |
| CN107771083A (en) * | 2015-04-23 | 2018-03-06 | 卡莱多生物科技有限公司 | Glycan therapeutic agent and treatment method |
| US9732071B2 (en) * | 2015-10-01 | 2017-08-15 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
| CN105309782A (en) * | 2015-10-21 | 2016-02-10 | 滁州红琊山养殖有限公司 | Orange-flavor pig feed flavoring agent |
| CN105558378A (en) * | 2015-12-30 | 2016-05-11 | 双胞胎（集团）股份有限公司 | Feed additive with effects in enhancing pig immunity and protecting nutrient components in feed |
| US20170087199A1 (en) * | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
| CN107468528A (en) * | 2016-06-07 | 2017-12-15 | 董玲 | A kind of lyophilized formulations and preparation method thereof |
| CN106071297A (en) * | 2016-06-08 | 2016-11-09 | 黄名珠 | A kind of duck feed that can improve egg production |
| CN105961904A (en) * | 2016-06-22 | 2016-09-28 | 桂轩 | Feed formula of meat ducks |
| US20160376263A1 (en) * | 2016-07-26 | 2016-12-29 | Senomyx, Inc. | Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof |
| CN106854247A (en) * | 2016-12-12 | 2017-06-16 | 华南农业大学 | A kind of preparation method of the bacterial virus catenase that can crack Escherichia coli and salmonella |
| CN108333263A (en) * | 2017-01-20 | 2018-07-27 | 北京蛋白质组研究中心 | A kind of detection method of Urine proteins preparation method and urine protein group |
| CN108392473A (en) * | 2017-02-07 | 2018-08-14 | 常州柚盾实业投资有限公司 | A kind of formula and preparation method thereof of the stable freeze-dried preparation containing active oil |
| CN106928908A (en) * | 2017-02-19 | 2017-07-07 | 广州市芯检康生物科技有限公司 | A kind of new aeroge multifunctional material and preparation method thereof |
| CN107156538A (en) * | 2017-06-03 | 2017-09-15 | 合肥雪立歆农业科技有限公司 | A kind of aquatic feeds of starch-containing adhesive and preparation method thereof |
| CN109106736A (en) * | 2017-06-25 | 2019-01-01 | 常州伟博海泰生物科技有限公司 | A kind of lyophilized excipient containing plant tissue |
| CN111032642A (en) * | 2017-06-29 | 2020-04-17 | 里格尔药品股份有限公司 | Kinase inhibitors and methods of making and using |
| CN107828769A (en) * | 2017-09-28 | 2018-03-23 | 昆明理工大学 | A kind of heat-resisting lyases MMPpgh and the polynucleotides for encoding this enzyme |
| CN108056325A (en) * | 2018-01-08 | 2018-05-22 | 浙江大学舟山海洋研究中心 | A kind of seawater black porgy fish meal with immunological enhancement |
| CN108342375A (en) * | 2018-03-22 | 2018-07-31 | 昆明三正生物科技（集团）有限公司 | A kind of Pintsch process enzymatic compositions |
| CN108926493A (en) * | 2018-08-24 | 2018-12-04 | 广东丸美生物技术股份有限公司 | A kind of skin care mantle compound powder and the preparation method and application thereof |
| CN112063538A (en) * | 2020-09-25 | 2020-12-11 | 中国农业科学院特产研究所 | Trichoderma hamatum, microbial agent containing trichoderma hamatum and application of trichoderma hamatum |
Non-Patent Citations (6)
| Title |
|---|
| XIAO SUYAO等: ""Preparation of folate conjugated starch nanoparticles and its application to tumor-targeted drug delivery vector"", 《CHINESE SCIENCE BULLETIN》 * |
| YU MI等: ""Enzyme-responsive multistage vector for drug delivery to tumor tissue"", 《PHARMACOL RES》 * |
| 嵇歆彧: ""高温噬菌体裂解酶TSPpgh的抑菌作用研究"", 《中国优秀硕士学位论文全文数据库 基础科学辑》 * |
| 张关令: ""复合裂解酶的制备及其在肉鸡饲养中的应用效果评价"", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 林海蛟等: ""添加剂对硅藻土吸附固定化脂肪酶的作用研究"", 《江西农业大学学报》 * |
| 熊燕: ""亚栖热菌噬菌体MMP7的基因组及裂解酶MMPpgh的特征"", 《中国优秀硕士学位论文全文数据库 基础科学辑》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110592057A (en) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | Chimeric lyase ILTphg and polynucleotides encoding same |
| CN110592057B (en) * | 2019-09-27 | 2022-01-28 | 昆明理工大学 | Chimeric lyase ILTphg and polynucleotides encoding same |
| CN111304181A (en) * | 2020-02-17 | 2020-06-19 | 华东理工大学 | Genetically engineered vibrio parahemolyticus phage lyase and preparation method and application thereof |
| CN111304181B (en) * | 2020-02-17 | 2021-11-23 | 华东理工大学 | Genetically engineered vibrio parahemolyticus phage lyase and preparation method and application thereof |
| CN111876400A (en) * | 2020-08-06 | 2020-11-03 | 昆明理工大学 | Normal temperature lyase Sly and polynucleotide for coding same |
| CN111876400B (en) * | 2020-08-06 | 2022-05-24 | 昆明理工大学 | Normal temperature lyase Sly and polynucleotide for coding same |
| CN112143747A (en) * | 2020-09-09 | 2020-12-29 | 昆明理工大学 | Phage lyase, gene thereof, gene recombination expression vector and application |
| CN115428862A (en) * | 2021-06-02 | 2022-12-06 | 菲吉乐科(南京)生物科技有限公司 | Antibacterial product produced by bacteriophage and lyase and preparation method thereof |
| CN116036101A (en) * | 2023-01-29 | 2023-05-02 | 广东省农业科学院动物科学研究所 | Application of trehalose in medicines for improving drug-resistant bacteria sensitivity and assisting chicken disease-resistant breeding |
| CN116036101B (en) * | 2023-01-29 | 2023-10-03 | 广东省农业科学院动物科学研究所 | Application of trehalose in improving drug-resistant bacteria sensitivity and assisting chicken disease-resistant breeding |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110592056A (en) | Phage lyase composite powder and preparation method and application thereof | |
| CN111534446B (en) | Lactobacillus reuteri and application thereof | |
| CN109337841B (en) | Bacillus subtilis BYS2 with efficient antibacterial performance | |
| CN113170842B (en) | Composite microecological preparation for preventing and treating necrotic enteritis of poultry and application thereof | |
| CN113040390B (en) | Probiotic salt-tolerant lactobacillus johnsonii and application thereof in preventing and treating pathogenic bacteria in livestock and poultry aquiculture | |
| CN111893066B (en) | Bacillus amyloliquefaciens SCAU-070 and application thereof | |
| JP2009232702A (en) | New lactic acid bacterium strain and utilization thereof | |
| KR102130646B1 (en) | Novel lactobacillus salivarius and feed additives for aquacultural fish and crustacea comprising the same | |
| CN113151035B (en) | Bacillus amyloliquefaciens, screening method, identification method and application | |
| CN116064324B (en) | Lactobacillus rhamnosus, culture method thereof and application thereof in preventing and treating diarrhea and enteritis | |
| KR20190047756A (en) | A composition comprising lactobacillus probiotics and a functional feed additive comprising the same | |
| CN108546661B (en) | Application method and preparation method of bacteriostatic microbial starter | |
| KR20140143497A (en) | Novel strain of Bacillus amyloliquefaciens and animal feed additive containing it | |
| EP2040723B1 (en) | Lactic acid bacterium with increased acid tolerance | |
| CN113637615B (en) | Weissella confusa, culture method and application thereof | |
| CN114085789B (en) | Pediococcus pentosaceus MA.WTPQJ01 and application thereof | |
| CN112704153B (en) | Immunodeficient mouse feed and preparation method thereof | |
| CN111944729B (en) | High-temperature-resistant lactobacillus plantarum microbial inoculum and preparation method and application thereof | |
| CN114075519B (en) | Bacillus megatherium tomb and application thereof in prawn culture and preparation of medicines | |
| JPH05292947A (en) | Lactobacillus-acidophilus pn-ri-2-4, lactic acid bacterial formulation using the same and its production | |
| CN114015626A (en) | Lactobacillus plantarum-like bacteria with bacteriostatic function, composite preparation thereof and application | |
| CN113729109B (en) | Fermented feed rich in antibacterial substances and preparation method thereof | |
| CN106260507B (en) | Application of lactobacillus johnsonii in food calling | |
| CN111100808A (en) | Lactobacillus plantarum and application thereof | |
| CN114836338B (en) | Lactobacillus rhamnosus A5 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |
|
| RJ01 | Rejection of invention patent application after publication |